The bottom-up “spaghetti organization” for breakthrough innovation at Oticon worked for nearly two decades to drive sales, but gradually became too fragmented and expensive as the company grew. The failure of a costly launch of a revolutionary new product, together with the appointment of a new president, led to a reshaping of the innovation process …
There is no abstract available for this product.
The case series describes the strategic transformation at Takeda, the largest Japanese pharmaceutical company, with a special focus on the R&D function. Since 2015, the 237-year-old industry dean has reduced his strategic focus from six to three. therapeutic areas, has reorganized its global R&D presence into one Japanese location and two in the US, and …
Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that makes products that will enhance existing therapeutic treatments for cancer, atherosclerosis, and retinal diseases, considered a $ 60 million private placement in February 2000. The company had more cash than ever, but the R&D and marketing spending projections were also unprecedented. PCYC’s most promising cancer drug, a radiation …
In August 1998, Kerry King, President and CEO of Ultratech Corp., watched the changes in the technology industry with great interest. Ultratech Corp. had the opportunity to complete a strategic merger that would make the combined company the undisputed leader in its market segment. The transaction, a multi-billion dollar deal, made perfect sense to Kerry, …
On Wednesday, July 6, 2011, the director of communications for the Canadian Cancer Society (CCS) in Toronto, Ontario, faced a difficult situation. The Canadian Broadcasting Corporation (CBC) had just published an article online that focused on the 2011 CCS budget, more specifically on how the CCS allocates millions of dollars each year. In addition, the …
It examines CIBA Vision’s decision on whether to launch a major new R&D initiative to develop low-cost disposable contact lenses for the day, and how such a project should be organized if it continues. A group of executives prefers to build a small, self-contained project team that is organizationally and geographically isolated from the company’s …
Chemical Bank’s private client division faces declining margins and increased competition in the loan, deposit collection and processing business. You would like to implement a new strategy to become a preferred financial services provider for target groups of clients. The division is adapting the balanced scorecard to clarify and communicate the new strategy and identify …
Nucleon is a small biotech company whose first potential product is close to clinical testing. However, before Nucleon can begin clinical trials, management must decide how and where to manufacture the product. Three options are being considered: 1) build our own pilot plant, 2) outsource manufacturing, 3) license development, manufacturing and marketing rights to a …
An overview of the new drug development process in the US Using the example of the migraine drug Imitrex.